Peripheral neuropathy and ototoxicity of dichlorodiamineplatinum: instrumental evaluation. Preliminary results.
Clinical use of cis-platinum in the treatment of many human tumors is increasing. Since side effects could represent a limitation of its use, we evaluated neurotoxic effects of this compound in a group of 23 patients on antiblastic treatment for gynecological neoplasms. Evaluation was performed by clinical-neurological examination, neurophysiological data (electromyography, maximal motor conduction velocity, and sensory conduction velocity) and potentials. Seven patients reported subjective symptoms of neurological involvement. In 2 cases there was a change in the electromyographic pattern. The otolaryngological examination showed a change in the hearing threshold in 3 patients and in 1 case the fatigue test was positive. Neurotoxic effects and hearing damage was not related to the treatment schedule.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001299:Audiometry; D002277:Carcinoma / Q000188:drug therapy; D002822:Choriocarcinoma / Q000188:drug therapy; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D004576:Electromyography; D005260:Female; D006311:Hearing Disorders / Q000139:chemically induced*; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000503:physiopathology; D011247:Pregnancy
D002945:Cisplatin